Showing 2661-2670 of 3810 results for "".
Laser Therapy for Atrophic Acne Scars: A Case and Evidence-based Updates
https://practicaldermatology.com/topics/acne-rosacea/laser-therapy-for-atrophic-acne-scars-a-case-and-evidence-based-updates/23737/Newly Approved Therapies for the Treatment of Plaque Psoriasis in Adults
https://practicaldermatology.com/topics/psoriasis/newly-approved-therapies-for-the-treatment-of-plaque-psoriasis-in-adults/23213/Here’s a closer a look at recently approved agents.The Role of Hypnosis in Dermatology: More than Mere Suggestion
https://practicaldermatology.com/columns/clinical-focus-1/the-role-of-hypnosis-in-dermatology-more-than-mere-suggestion/23240/Hypnosis has shown promising results for patients who have had difficulty responding to more conventional therapies.Diagnosing and Managing Hair Disorders
https://practicaldermatology.com/topics/general-topics/diagnosing-and-managing-hair-disorders/20624/From loss to overgrowth, hair disorders may be associated with systemic causes.Turmeric, Curcumin, and Curcuminoids: A Dermatologic Review
https://practicaldermatology.com/columns/clinical-focus-1/turmeric-curcumin-and-curcuminoids-a-dermatologic-review/23377/Curcumin, one of the active compounds of turmeric, exhibits anti-inflammatory, antimicrobial, antioxidant, anti-nociceptive, and antineoplastic properties.Cutaneous T-Cell Lymphoma: Mogamulizumab as a Novel Treatment for Refractory Mycosis Fungoides and Sezary Syndrome
https://practicaldermatology.com/youngmd-connect/resident-resource-center/Cutaneous-T-Cell-Lymphoma-Mogamulizumab-as-a-Novel-Treatment-for-Refractory-Mycosis-Fungoides-and-Sezary-Syndrome/23409/An overview of the diagnosis and prognosis of CTCL.Choosing the Best Medical Website Provider
https://practicaldermatology.com/topics/practice-management/choosing-the-best-medical-website-provider/22967/Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.The Role of GLP-1RAs in Treating Inflammatory Dermatologic Diseases
https://practicaldermatology.com/issues/novemberdecember-2025/the-role-of-glp-1ras-in-treating-inflammatory-dermatologic-diseases/48899/Herein, we review the benefits and risks of GLP-1RAs with a focus on these 3 chronic inflammatory conditions.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.